Otonomy to Report Third Quarter 2021 Financial Results and Provide Corporate Update

Rhea-AI Summary

Otonomy, Inc. (Nasdaq: OTIC) announced it will release its third quarter 2021 financial results and provide a corporate update on November 10, 2021, at 4:30 p.m. ET. Investors can join the call by dialing (877) 305-6769 for domestic or (678) 562-4239 for international participants, using conference ID 3812898. A live webcast will also be available on the company's investor relations website. Otonomy focuses on developing innovative therapeutics for neurotology, utilizing drug delivery technology to address hearing loss and tinnitus.

Positive

• Upcoming corporate update may provide insights into progress and future strategies.
• Focus on hearing loss and tinnitus indicates potential for addressing significant unmet medical needs.

Negative

• None.

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the third quarter 2021 and provide a corporate update at 4:30 p.m. ET (1:30 p.m. PT) on November 10, 2021.

The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 3812898. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.otonomy.com.

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information, please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Chloé-Anne Ramsey
Vice President
404.865.3601
cramsey@spectrumscience.com

Investor Inquiries:
ICR Westwicke
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

When will Otonomy report its third quarter 2021 financial results?

Otonomy will report its third quarter 2021 financial results on November 10, 2021.

How can I access the Otonomy earnings call?

You can access the earnings call by calling (877) 305-6769 for domestic or (678) 562-4239 for international callers.

What is the conference ID for the Otonomy earnings call?

The conference ID for the Otonomy earnings call is 3812898.

What is Otonomy's focus in the biopharmaceutical industry?

Otonomy focuses on developing innovative therapeutics for neurotology, particularly addressing hearing loss and tinnitus.